Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer

International Journal of Oncology

Volumn 27, Issue 5, 2005, Pages 1215-1221

  Nakano, Jun ^a   Huang, Cheng Long ^a   Liu, Dage ^a   Ueno, Masaki ^a   Sumitomo, Shinichi ^b   Yokomise, Hiroyasu ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b JAPANESE RED CROSS WAKAYAMA MEDICAL CENTER   (Japan)

Author keywords

Apoptosis; Lung cancer; P53; Proliferation; Survivin

Indexed keywords

BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; PROTEIN P53; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33644642710     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.5.1215     Document Type: Article

References (43)

1. Cersosimo RJ: Lung cancer: a review. Am J Health Syst Pharm 59:611-642,2002.
2. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J and International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350: 351-360, 2004.
3. Martin J, Ginsberg RJ, Venkatraman ES, Bains MS, Downey RJ, Korst RJ, Kris MG and Rusch VW: Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J Clin Oncol 20: 1989-1995, 2002.
4. Vogelstein B and Kinzler KW: p53 function and dysfunction. Cell 70: 523-526,1992.
5. Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22: 8581-8589,2003.
6. Strasser A, Huang DC and Vaux DL: The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochim Biophys Acta 1333: F151-F178,1997.
7. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC and Mason DY: bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329: 690-694, 1993.
8. Huang C, Kohno N, Inufusa H, Kodarna K, Taki T and Miyake M: Overexpression of bax associated with mutations in the loopsheet-helix motif of p5 3. Am J Pathol 155: 955-965,1999.
9. Tanaka F, Otake Y, Yanagihara K, Yamada T, Miyahara R, Kawano Y, Li M, Inui K and Wada H: Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer. Br J Cancer 84: 263-269, 2001.
10. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921,1997.
11. Lu CD, Altieri DC and Tanigawa N: Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58: 1808-1812,1998.
12. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T and Tanigawa N: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58: 5071-5074, 1998.
13. Morinaga S, Nakamura Y, Ishikawa N, Yoshikawa T, Noguchi Y, Yamamoto Y, Rino Y, Imada T, Takanishi Y, Akaike M, Sugimasaa Y and Takemiya S: Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma. Oncol Rep 12:1189-1194,2004.
14. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K and Tokuda M: Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol 21: 315-320, 2002.
15. Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, Martin C, Font A, Barnadas A and Abad A: A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 17: 2100-2104,1999.
16. Salvesen GS and Duckett CS: IAP proteins: blocking the road to death′s door. Nat Rev Mol Cell Biol 3: 401-410, 2002.
17. Greenblatt MS, Bennett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
18. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW and Vogelstein B: Definition of a consensus binding site for p53. Nat Genet 1:45-49, 1992.
19. Velculescu VE and El-Deiry WS: Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 42: 858-868,1996.
20. Hoffman WH, Biade S, Zilfou JT, Chen J and Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277: 3247-3257, 2002.
21. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB and Liu S: Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21: 2613-2622, 2002.
22. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U and Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715,1984.
23. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717,1997.
24. Yamada Y, Kuroiwa T, Nakagawa T, Kajimoto Y, Dohi T, Azuma H, Tsuji M, Kami K and Miyatake S: Transcriptional expression of survivin and its splice variants in brain tumors in humans. J Neurosurg 99: 738-745, 2003.
25. Huang C, Taki T, Adachi M and Konishi T, Higashiyama M and Miyake M: Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer. Oncogene 16: 2469-2477, 1998.
26. Deveraux QL and Reed JC: IAP family proteins - suppressors of apoptosis. Genes Dev 13: 239-252, 1999.
27. Ambrosini G, Adida C, Sirugo G and Altieri DC: Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 273: 11177-11182,1998.
28. Olie RA, Simoes-Wust P, Baumann B, Leech SH, Fabbro D, Stahel RA, and Zangemeister-Wittke U: A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60:2805-2809,2000.
29. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584, 1998.
30. Adams RR, Carmena M and Earnshaw WC: Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol 11:49-54,2001.
31. Falleni M, Pellegrini C, Marchetti A, Oprandi B, Buttitta F, Barassi F, Santambrogio L, Coggi G and Bosari S: Survivin gene expression in early-stage non-small cell lung cancer. J Pathol 200: 620-626, 2003.
32. Nakanishi K, Kawai T, Kumaki F, Hiroi S, Mukai M and Ikeda E: Survivin expression in atypical adenomatous hyperplasia of the lung. Am J Clin Pathol 120: 712-719, 2003.
33. Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE and Gerharz CD: Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 9: 1334-1342,2002.
34. Mahotka C, Wenzel M, Springer E, Gabbert HE and Gerharz CD: Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59: 6097-6102, 1999.
35. Muzio LL, Pannone G, Staibano S, Mignogna MD, Rubini C, Mariggio MA, Procaccini M, Ferrari F, Rosa GD and Altieri DC: Survivin expression in oral squamous cell carcinoma. Br J Cancer 89: 2244-2248, 2003.
36. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAFl, a potential mediator of p53 tumor suppression. Cell 75-817-825,1993.
37. Miyashita T and Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299 1995.
38. Sandri MI, Isaacs RJ, Ongkeko WM, Harris AL, Hickson ID, Broggini M and Vikhanskaya F: p53 regulates the minimal promoter of the human topoisomerase Ilalpha gene. Nucleic Acids Res 24: 4464-4470,1996.
39. Krysan K, Merchant FH, Zhu L, Dohadwala M, Luo J, Lin Y, Heuze-Vourch N, Pold M, Seligson D, Chia D, Goodglick L, Wang H, Strieter R, Sharma S and Dubinett S: COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J 18:206-208,2004.
40. Lu B, Gonzalez A, Massion PP, Shyr Y, Shaktour B, Carbone DP and Hallahan DE: Nuclear survivin as a biomarker for nonsmall-cell lung cancer. Br J Cancer 91: 537-540,2004.
41. Kren L, Brazdil J, Hermanova M, Goncharuk VN, Kallakury BVS, Kaur P and Ross JS: Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases. Appl Immunohistochem Mol Morphol 12: 44-49, 2004.
42. Lu B, Mu Y, Cao C, Zeng F, Schneider S, Tan J, Price J, Chen J, Freeman M and Hallahan DE: Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 64: 2840-2845,2004.
43. Ning S, Fuessel S, Kotzsch M, Kraemer K, Kappier M, Schmidt U, Taubert H, Wirth MP and Meye A: siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol 25: 1065-1071, 2004.